文献速递神经肿瘤

干扰素调节因子8驱动的免疫微环境重编程增强小鼠胶质母细胞瘤的抗肿瘤适应性免疫并减少免疫抑制

Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma.
PubMed 文献 · Neuro Oncol · 2024-01-01

本研究利用逆转录病毒复制载体(RRV)在小鼠SB28胶质母细胞瘤(GBM)模型中递送干扰素调节因子8(IRF8),发现瘤内注射RRV-IRF8可显著抑制肿瘤生长并延长生存期,其机制与cDC1和CD8+ T细胞富集、髓系细胞免疫抑制标志物Arg1和IDO1表达下降及抗原呈递增强相关,且IRF8转导肿瘤与非肿瘤细胞对生存获益均为必要。

要点

  • 瘤内注射RRV-IRF8可显著抑制小鼠SB28胶质母细胞瘤生长并延长生存期。
  • RRV-IRF8治疗肿瘤中cDC1和CD8+ T细胞显著富集,髓系细胞Arg1和IDO1表达下降。
  • IRF8在肿瘤与非肿瘤细胞中的转导对生存获益均为必要,与cDC1和CD8 T细胞富集的微环境相关。

核心结论

  • 通过体内表达IRF8重编程胶质瘤浸润髓系细胞可能减少免疫抑制并增强抗原呈递,从而实现更好的肿瘤控制。

研究设计与样本

  • 在SB28小鼠胶质母细胞瘤模型中,使用逆转录病毒复制载体(RRV)递送IRF8,检测生存和肿瘤生长动力学,并通过流式细胞术和基因表达分析免疫表型,用离体T细胞-髓系细胞共培养评估免疫抑制和抗原呈递功能。

主要发现

  • 瘤内注射RRV-IRF8显著抑制颅内SB28胶质瘤生长并延长生存期。
  • RRV-IRF8治疗肿瘤中cDC1和CD8+ T细胞显著富集。
  • RRV-IRF8肿瘤来源的髓系细胞免疫抑制标志物Arg1和IDO1表达下降,且与对照相比,在离体共培养中对初始T细胞增殖的抑制减少。
  • RRV-IRF8肿瘤来源的树突状细胞与对照肿瘤相比抗原呈递增加。
  • 体内使用病毒复制抑制剂齐多夫定(AZT)显示,IRF8在肿瘤和非肿瘤细胞中的转导对生存获益均为必要,并与重编程的cDC1和CD8 T细胞富集的肿瘤免疫微环境相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) has a highly immunosuppressive tumor immune microenvironment (TIME), largely mediated by myeloid-derived suppressor cells (MDSCs). Here, we utilized a retroviral replicating vector (RRV) to deliver Interferon Regulatory Factor 8 (IRF8), a master regulator of type 1 conventional dendritic cell (cDC1) development, in a syngeneic murine GBM model. We hypothesized that RRV-mediated delivery of IRF8 could "reprogram" intratumoral MDSCs into antigen-presenting cells and thereby restore T-cell responses. METHODS: Effects of RRV-IRF8 on survival and tumor growth kinetics were examined in the SB28 murine GBM model. The immunophenotype was analyzed by flow cytometry and gene expression assays. We assayed functional immunosuppression and antigen presentation by ex vivo T-cell-myeloid co-culture. RESULTS: Intratumoral injection of RRV-IRF8 in mice bearing intracerebral SB28 glioma significantly suppressed tumor growth and prolonged survival. RRV-IRF8 treated tumors exhibited significant enrichment of cDC1s and CD8+ T-cells. Additionally, myeloid cells derived from RRV-IRF8 tumors showed decreased expression of the immunosuppressive markers Arg1 and IDO1 and demonstrated reduced suppression of naïve T-cell proliferation in ex vivo co-culture, compared to controls. Furthermore, DCs from RRV-IRF8 tumors showed increased antigen presentation compared to those from control tumors. In vivo treatment with azidothymidine (AZT), a viral replication inhibitor, showed that IRF8 transduction in both tumor and non-tumor cells is necessary for survival benefit, associated with a reprogrammed, cDC1- and CD8 T-cell-enriched TIME. CONCLUSIONS: Our results indicate that reprogramming of glioma-infiltrating myeloid cells by in vivo expression of IRF8 may reduce immunosuppression and enhance antigen presentation, achieving improved tumor control.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Montoya M, Collins SA, Chuntova P, et al. Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma. Neuro Oncol. 2024. PMID: 39115195. doi:10.1093/neuonc/noae149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。